...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Due Dilligence
Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of the BET Bromodomain Inhibitor ZEN-3694
Posted by:
BearDownAZ
on
Jul 22, 2021 09:56AM
Triple Negative Breast Cancer Drug Development Digital Summit 4/29/2021
Posted by:
BearDownAZ
on
Jun 24, 2021 04:13PM
Zenith Epigenetics Links
Zenith_AGM_2018_09_12... (rough)
Zenith 2018 AGM transcript c/o imtesty
Posted by:
kelsee
on
Sep 20, 2018 10:08AM
Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Posted by:
BearDownAZ
on
Sep 04, 2018 11:52AM
Zenith News
See company provided event list here: https://www.zenithepigenetics.com/newsroom/events. Check out Zenith Agoracom link library here: https://agoracom.com/ir/ZenithEpigenetics/links
Posted by:
BearDownAZ
on
Sep 04, 2018 11:44AM